StockNews.com initiated coverage on shares of RedHill Biopharma (NASDAQ:RDHL – Free Report) in a research report sent to investors on Thursday. The firm issued a hold rating on the biotechnology company’s stock.
RedHill Biopharma Stock Performance
Shares of NASDAQ RDHL opened at $2.56 on Thursday. RedHill Biopharma has a 1 year low of $2.47 and a 1 year high of $20.28. The firm’s 50 day moving average price is $5.05 and its 200 day moving average price is $7.04.
Hedge Funds Weigh In On RedHill Biopharma
An institutional investor recently bought a new position in RedHill Biopharma stock. GAMMA Investing LLC purchased a new position in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 5,089 shares of the biotechnology company’s stock, valued at approximately $32,000. GAMMA Investing LLC owned 0.40% of RedHill Biopharma as of its most recent SEC filing. 7.20% of the stock is owned by institutional investors.
RedHill Biopharma Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
Featured Stories
- Five stocks we like better than RedHill Biopharma
- Which Wall Street Analysts are the Most Accurate?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Are Penny Stocks a Good Fit for Your Portfolio?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
